Iranian Red Crescent Medical Journal

Published by: Kowsar

Cloning of the Recombinant Cytochrome P450 Cyp141 Protein of Mycobacterium tuberculosis as a Diagnostic Target and Vaccine Candidate

Mohammad Rabiee-Faradonbeh 1 , 2 , Davood Darban Sarokhalil 3 , Mohammad Mehdi Feizabadi 4 , Amirhooshang Alvandi 4 , Hasan Momtaz 2 , Neda Soleimani 6 and Abolfazl Gholipour 1 , *
Authors Information
1 Department of Microbiology and Immunology, Faculty of Medicine, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, IR Iran
2 Department of Microbiology, Shahrekord Branch, Islamic Azad University, Shahrekord,IR Iran
3 Department of Microbiology and Immunology, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
4 Department of Microbiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
6 Department of Pathology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: November 01, 2014, 16 (11); e18001
  • Published Online: October 5, 2014
  • Article Type: Research Article
  • Received: February 9, 2014
  • Revised: April 8, 2014
  • Accepted: April 23, 2014
  • DOI: 10.5812/ircmj.18001

To Cite: Rabiee-Faradonbeh M, Darban Sarokhalil D, Feizabadi M M, Alvandi A, Momtaz H, et al. Cloning of the Recombinant Cytochrome P450 Cyp141 Protein of Mycobacterium tuberculosis as a Diagnostic Target and Vaccine Candidate, Iran Red Crescent Med J. 2014 ; 16(11):e18001. doi: 10.5812/ircmj.18001.

Abstract
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine. 2007; 25(19): 3742-51[DOI][PubMed]
  • 2. WHO Report Global Tuberculosis Control: Epidemiology, Strategy, Financing. 2012;
  • 3. Neonakis IK, Gitti Z, Krambovitis E, Spandidos DA. Molecular diagnostic tools in mycobacteriology. J Microbiol Methods. 2008; 75(1): 1-11[DOI][PubMed]
  • 4. Smith R. Eradication of tuberculosis by 2050 impossible without new vaccine. BMJ. 2009; 338[DOI][PubMed]
  • 5. Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 2011; 8(8)[DOI][PubMed]
  • 6. Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect Immun. 2008; 76(9): 4190-8[DOI][PubMed]
  • 7. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346(8986): 1339-45[PubMed]
  • 8. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet. 2010; 375(9731): 2110-9[DOI][PubMed]
  • 9. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999; 284(5419): 1520-3[PubMed]
  • 10. McLean KJ, Dunford AJ, Neeli R, Driscoll MD, Munro AW. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems. Arch Biochem Biophys. 2007; 464(2): 228-40[DOI][PubMed]
  • 11. Darban-Sarokhalil D, Fooladi AA, Bameri Z, Nasiri MJ, Feizabadi MM. Cytochrome CYP141: a new target for direct detection of Mycobacterium tuberculosis from clinical specimens. Acta Microbiol Immunol Hung. 2011; 58(3): 211-7[DOI][PubMed]
  • 12. Mustafa AS. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb). 2005; 85(5-6): 367-76[DOI][PubMed]
  • 13. Cohen S. Challenges influencing the future of endodontics. New technologies for endodontic education. Aust Endod J. 2001; 27(3): 116-8[PubMed]
  • 14. Chitlaru T, Shafferman A. Proteomic studies of Bacillus anthracis. Future Microbiol. 2009; 4(8): 983-98[DOI][PubMed]
  • 15. Kashino SS, Pollock N, Napolitano DR, Rodrigues V, Jr., Campos-Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. 2008; 153(1): 56-62[DOI][PubMed]
  • 16. Sumithra TG, Chaturvedi VK, Rai AK, Chougule SS, Rajan LS, Jacob SS, et al. Progress in DNA Vaccinology against Bacterial Diseases–An Update. Adv Anim Vet Sci. 2013; 1(6): 164-77
  • 17. Dominguez J, Gali N, Blanco S, Pedroso P, Prat C, Matas L, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest. 2001; 119(1): 243-9[PubMed]
  • 18. Gholipour A, Moosavian M, Galehdari H, Makvandi M, Memari HR, Alvandi AH. Cloning and periplasmic expression of peptidoglycan-associated lipoprotein (PAL) protein of Legionella pneumophila in Escherichia coli. Jundishapur J Microbiol. 2010; 3(1): 1-9
  • 19. Gholipour A, Moosavian M, Makvandi M, Galehdari H, Alvandi A, Mard SA. Development of an indirect sandwich ELISA for detection of urinary antigen, using Legionella pneumophila PAL protein. World J Microbiol Biotechnol. 2014; 30(5): 1463-71[DOI][PubMed]
  • 20. Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am. 2010; 24(3): 751-68[DOI][PubMed]
  • 21. van Helden PD, Hoal EG. A new TB vaccine: fact or fiction? Comp Immunol Microbiol Infect Dis. 2013; 36(3): 287-94[DOI][PubMed]
  • 22. Jassal MS, Bishai WR. Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis. 2010; 50 Suppl 3-64[DOI][PubMed]
  • 23. Martin Montanes C, Gicquel B. New tuberculosis vaccines. Enferm Infecc Microbiol Clin. 2011; 29: 57-62[DOI]
  • 24. Piubelli L, Campa M, Temporini C, Binda E, Mangione F, Amicosante M, et al. Optimizing Escherichia coli as a protein expression platform to produce Mycobacterium tuberculosis immunogenic proteins. Microb Cell Fact. 2013; 12: 115[DOI][PubMed]
  • 25. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect Immun. 2001; 69(4): 2714-7[DOI][PubMed]
  • 26. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol. 2010; 17(5): 793-801[DOI][PubMed]
  • 27. Lu J, Wang C, Zhou Z, Zhang Y, Cao T, Shi C, et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Dev Immunol. 2011; 2011: 617892[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments